TABLE 9.
Activities and spectra of activity of 11 representatives of non-β-lactam drug classes tested against the four most prevalent causes of gram-negative bacteremia in Canada
| Antimicrobial class and agent tested | Activity againsta:
|
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
E. coli (181)
|
Klebsiella (53)
|
P. aeruginosa (45)
|
Enterobacter (34)
|
|||||||||
| MIC range | MIC50/ MIC90 | % S | MIC range | MIC50/ MIC90 | % S | MIC range | MIC50/ MIC90 | % S | MIC range | MIC50/ MIC90 | % S | |
| Aminoglycosides | ||||||||||||
| Amikacin | ≤0.25–>32 | 4/8 | 98.9 | 0.5–8 | 2/4 | 100 | 0.5–>32 | 4/16 | 95.5 | 1–>32 | 2/4 | 96.9 |
| Gentamicin | ≤0.12–>16 | 1/4 | 94.3 | ≤0.12–>16 | 0.5/2 | 94.1 | 0.25–>16 | 2/8 | 84.1 | 0.5–2 | 1/2 | 100 |
| Tobramycin | ≤0.12–>16 | 94.4 | 96.7 | 0.25–16 | 1/1 | 96.1 | ≤0.012–>16 | 1/2 | 95.5 | 0.5–>16 | 1/1 | 96.9 |
| Fluoroquinolones | ||||||||||||
| Ciprofloxacin | ≤0.015–>2 | ≤0.015/0.06 | 96.6 | ≤0.015–>2 | 0.3/0.12 | 98.0 | 0.03–>2 | 0.12/>2 | 79.5 | ≤0.015–0.25 | ≤0.015/0.06 | 100 |
| Ofloxacin | ≤0.03–>4 | 0.06/0.12 | 96.6 | ≤0.03–>4 | 0.12/0.25 | 98.0 | 0.25–>4 | 1/>4 | 63.6 | 0.06–0.12 | 0.12/0.12 | 100 |
| Levofloxacin | ≤0.5–>4 | ≤0.5/≤0.5 | 97.2 | ≤0.5–>4 | ≤0.5/≤0.5 | 98.0 | ≤0.5–>4 | ≤0.5/>4 | 70.5 | ≤0.5 | ≤0.5/≤0.5 | 100 |
| Sparfloxacinc | ≤0.25–>2 | ≤0.25/≤0.25 | —b | ≤0.025–>2 | ≤0.25/≤0.25 | — | ≤0.25–>2 | 1/>2 | — | ≤0.25 | ≤0.25/≤0.25 | — |
| Gatifloxacinc | ≤0.03–>4 | ≤0.03/0.06 | — | ≤0.03–>4 | 0.06/0.25 | — | 0.06–>4 | 1/>4 | — | ≤0.03–0.5 | 0.06/0.12 | — |
| Trovafloxacinc | ≤0.03–>4 | ≤0.03/0.12 | — | ≤0.03–>4 | 0.06/0.25 | — | ≤0.03–>4 | 0.5/>4 | — | ≤0.03–0.5 | 0.06/0.12 | — |
| Others | ||||||||||||
| Tetracycline | ≤4–>8 | ≤4/>8 | 73.3 | ≤4–>8 | ≤4/>8 | 80.4 | ≤4–>8 | >8/>8 | 4.5 | ≤4–>8 | ≤4/≤4 | 93.8 |
| Trimethoprim-sulfamethoxazole | ≤0.5–>1 | ≤0.5/>1 | 80.7 | ≤0.5–>1 | ≤0.5/>1 | 82.4 | ≤0.5–>1 | >1/>1 | 2.3 | ≤0.5–>1 | ≤0.5/≤0.5 | 96.9 |